EMY says a newer class of weight loss drugs is beating Ozempic. The drugs and the data behind the claim are not named, so tap through for the details.
Recap by typeshit. Full story at ΕΜΥ.
EMY covers findings suggesting GLP-1 drugs such as Wegovy could lower the risk of certain cancers. Details on which cancers are in the full story.
Shah points to research published September 2 in which older mice given semaglutide lived longer, with effects he says went beyond blood sugar control.
The review weighs weight and metabolic benefits in people with IBD against early lab hints of anti-inflammatory effects, and looks at what observational studies show so far.
The obesity doctor takes on why some people see weaker results on GLP-1 medications. Short clip with few details given.
A short piece on the effectiveness of Novo Nordisk's oral version of Wegovy. Only the headline is available, so tap through for the findings.
Rooney says the Ozempic rumors are wrong, that he is working to look better and be healthier, and that he has stopped drinking alcohol for a while.
Loading…